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Many feel that the R01 grant system supporting biomedical research in the U.S. is broken, discour-
aging entry of young investigators into the system and inadequately supporting more established
investigators. Here, I argue for a ‘‘person-not-project’’-based scheme that would permit creative,
unfettered research by new investigators, better tie ongoing research contributions to continued
funding, and help match the number of investigators seeking support with available funds.Background
An increasing number of commentaries
have highlighted the serious problems
with the present state of NIH-funded
biomedical research in the U.S. (Alberts
et al., 2014; Alberts et al., 2015; Casade-
vall and Fang, 2012; Daniels, 2015;
Lorsch, 2015; McKnight, 2015). Several
of these papers have emphasized the
competition for funding, the associated
discouragement of bright individuals
from seeking a career in research, the
reduction in research progress due to
the excessive time spent by investigators
preparing grant applications, and the
inhibition of creativity resulting from the
nature of the grant review process. In
many ways, these problems are all linked
to the current R01 grant system. What
was once a highly effective mechanism
for parceling out support to the most
deserving scientists has now evolved
intowhatmany investigators see as a stul-
tifying, regimented process in which form
often counts for more than content and in
which any proposal lacking substantial
evidence of already having been largely
accomplished is unlikely to be supported.
It is also a process in which the applicant
‘‘dissembles’’ about the true purpose
of the grant, given that most of the pro-
posed aims will necessarily have already
been accomplished to satisfy the need
for preliminary evidence, and the funding
will thus be used for research other
than that the grant asks for support to
accomplish.
Although these problems affect inves-
tigators at all stages of career progres-
sion, they are most damaging to thosecontemplating a future in research or
just beginning their independent research
careers. In the former case, there is a
keen appreciation of the disconnect that
exists between how a smart and hard-
working student succeeds in moving
along the educational pathway versus
the likelihood of success as a PI. The
ego structure of most scientists is one in
which the person believes that a combi-
nation of intelligence and effort begets
academic success. Accomplishments in
high school facilitate entrance into a
top college or university, where similar
traits allow accomplishments supporting
entrance into a top graduate or medical
school, and likewise through postdoctoral
training, and finally to the offer of a junior
faculty position at a top institution. But
then the vagaries of the R01 system
intrude, disconnecting the two traits that
unpinned success to this point from any
predictable success going forward (Fang
and Casadevall, 2014). The result is that
many of the best young ‘‘proto-scientists’’
are opting against pursuing a research
career. This was brought home through
the anecdotal (but I think cogent) experi-
ence of my son who majored in biology
and graduated from Stanford in 2009.
To his and my surprise, very few of
the 100 students graduating that year
with a degree in biology chose to move
on directly to Ph.D. programs. Although
some entered M.D. or M.D.-Ph.D. pro-
grams, many discussions at the depart-
mental graduation ceremony centered
on the theme of how much students
enjoyed their undergraduate scientific
research efforts but wanted or hadCell 16to plan for careers doing something
other than full-time basic science. These
choices were largely predicated on the
experiences these people had during
undergraduate research in top labora-
tories at Stanford. There they saw the
struggles and uncertainty faced by even
very successful postdocs and PIs and
decided that they did not want to take
the career risks the Ph.D./academic
research pathway posed.
With respect to those who have made it
to a junior faculty research appointment,
these individuals must often begin sub-
mitting R01 applications within a year or
two of starting their labs. This is not only
because of the need for additional funding
beyond start-up support but also because
this is demanded by the employing insti-
tution and promotion boards. In the past,
when perhaps 10%–15% of one’s time
was occupied with grant preparation,
this was not a problem, and there was
merit in the argument that such grant
preparation helped focus the thinking of
the investigator and resulted in more
productive research activity. But now,
50% or more of a faculty member’s time
can easily be spent in grant preparation.
For junior faculty, this drastically hampers
their ability to perform experiments them-
selves, at a time when they are the most
accomplished and effective member of
their laboratory staff. As a result, far too
many young investigators almost immedi-
ately retreat to their office, abandoning
the bench and relying on students
before they have fully established their
own research programs or learned how
to evaluate data generated by others.1, June 18, 2015 ª2015 Elsevier Inc. 1485
The consequences are clear: much less
efficient research and a tendency to be
conservative and do experiments that
can lead to ‘‘preliminary data’’ required
for grant applications, most often next
steps from postdoctoral research rather
than novel, creative studies, all at a slower
pace than should be the case.
Many of these problems affecting rising
scientists and junior faculty members can
be largely rectified by changes in how
biomedical science is funded. Rather
than supporting the project, it is time
for the majority of the R01-equivalent
research enterprise to move to the
investigator-centric support strategy of
the HHMI (HHMI, 2015), NIH intramural
program (National Institutes of Health,
2015a), and Wellcome Trust (Wellcome
Trust, 2015) (among others), a strategy
being considered by some NIH institutes
as a replacement to conventional proj-
ect-oriented grants for at least some
established investigators (Kaiser, 2014).
I have asked dozens of senior colleagues
to answer the following question: ‘‘If
I gave you $5 million to distribute for
research and said you could either have
the CV or a grant proposal, but not both,
from the applicants, which would you
choose to help guide distribution of the
funds?’’ The results are nearly 100%
votes for the CV—in contrast to financial
investments for which it is said ‘‘past
performance is no indication of future re-
turns,’’ in science, it is widely accepted
that past performance, not a detailed
research plan, is the best predictor of
future success. So why stay with the1486 Cell 161, June 18, 2015 ª2015 Elsevierfiction that R01 grant proposals are the
best method for determining support
of the individual scientist, given that, as
stated above, these grants now require
most of the work to have already been
accomplished at least in preliminary
form and that true creativity is often cause
for lower scores?
Proposal
To address these problems, including the
choice by some of the best and brightest
students in the U.S. not to pursue a career
in science, I believe the NIH should transi-
tion to a system that links getting a first
job (faculty appointment) with sufficient
funding to support a reasonably sized
laboratory (three to five people, including
the PI) in terms of staff salaries and sup-
plies, with the institution adding in some
support for faculty salary and large equip-
ment. How this linkage between jobs
and NIH funding should be accomplished
is described in detail below.
Once the new hire is in place, the
new faculty member then would have
5–7 years (this could vary among disci-
plines) to pursue whatever they wish,
with no need for conventional project-
specific R01 funding. At the end of this
time, they would be evaluated for further
funding based on what they have accom-
plished (the review would be 90% retro-
spective, 10% on general, not detailed,
plans for future work). There would be
three main outcomes: (1) failure due to
lack of substantial output and contribu-
tions to the field, resulting in a cessation
of funding, (2) value added to the fieldInc.that permits continued but not increased
funding, and (3) stellar performance
(e.g., opening a new area of research),
which allows continued funding and a
request for expansion. There would be
two exceptions to the cutoff of funds for
people in the first outcome grouping:
(1) cases in which the investigators can
show that, within another year, they would
likely make a major advance or (2) cases
in which investigators tried something
extremely original or risky in the earlier
years of their appointment; the latter
could obtain 1–2 years of bridge funding
on a case-by-case basis. In addition,
due allowance for family and health-
related issues would be made in deter-
mining the timing of the initial reviewpoint.
This plan for new faculty would be
connected to a rolling change in the
present R01 grant mechanism among
more senior investigators by switching
to retrospective review in 5–7 year cycles
as the major grants of an individual come
due. If possible, it would be best to roll
all R01 grant award into one or two
new awards (if the breadth of research
requires support from more than a single
NIH institute) at a particular point for
each investigator, rather than to have
different reviews for different grants and
topics at varying times.
Several issues arise in terms of the
starting junior faculty proposal, first
among them being the source of the
funding. I believe that the bestmechanism
is to provide the appointing institution
with block grants that can only be used
for such new faculty support. This
is because the institutions make the
appointments, and a national parsing of
support would be hard to coordinate
with such hiring decisions in advance.
This is clearly a point of contention,
with many of those I spoke to about this
issue being opposed to institutional
award and favoring instead a national
NIH-operated competition on an
individual basis. I find the latter hard toimagine as workable—there are at least
200 open junior biomedical faculty posi-
tions every year spread across institutions
and departments, with >200–300 appli-
cants for each opening. Even accounting
for a 53 overlap in applicants for similar
positions, this would lead to >4,000
applications to evaluate per year and
brings us to the problem of study sections
and their make-up. Further, it wouldCell 16be difficult to align award with open fac-
ulty positions on a field or department ba-
sis. Other limitations to a scheme of indi-
vidual funding would be institutional
hiring based on a candidate having
money and not necessarily based on
merit or potential (the judgment of NIH
study sections is very likely not to match
that of faculty at the hiring institutions).
More discussion is certainly welcome,
and an even better scheme might emerge
from further consideration of this point.
Which institutions would get funding in
the proposed scheme and how would
the scale of the institutional awards be
determined? One logical possibility is
that, at the beginning of the launch of
this new plan, all institutions presently
with K22, K99, R21, R01, etc. awards for
their junior faculty would receive grants
whose scale is based on historical data
reflecting the institution’s receipt of such
awards over the past 10 years, factoring
in the increased costs associated with
full funding of a 3–5 person laboratory
for 5–7 years. In this way, one does not
need new dollars to get the program
started and there will be natural ‘‘popula-
tion control’’ in that institutions will be
constrained in the number of new ap-
pointments they can make. By making
renewal of the institutional block award
contingent on the funding rate of that
institution’s appointees upon their initial
retrospective review in the ‘‘new R01
regime’’ I outline above, the institutions
would be forced to provide a high level
of support andmentoring to the junior fac-
ulty to help ensure their success.Responses to Additional Caveats
Raised by Others
I have discussed this specific plan with
various HHMI investigators, tenured and
non-tenured faculty at diverse institu-
tions, postdoctoral fellows, and students
around the U.S. The responses range
from substantial interest to enormous
enthusiasm, most at the latter end of the
scale. The major questions raised about
the plan beyond those dealt with above
have been the following:
1. How would the money be appor-
tioned to support the program?
I have addressed this in part
above, but some have broached
the question of whether this would1, June 18, 2015 ª2015 Elsevier Inc. 1487
148make the ‘‘rich richer’’ and also
pose political problems because
of the skewed distribution of grants
and faculty in the current research
landscape. I think that both points
are valid but can be addressed.
First, no institution would get less
on average than they get now, so
the distribution is not ‘‘unfair’’ in
that regard. As to disadvantaging
an institution that is trying to ‘‘up
its game,’’ even in the present situ-
ation, this usually requires a large
upfront internal financial investment
from the institution (typically utiliz-
ing private or state dollars) to attract
faculty that it wouldn’t otherwise be
able to compete for, so this would
remain the same. However,
as renewal applications of existing
new faculty support block awards
come in, one would imagine that
some institutions will do more
poorly than others. Up-and-coming
institutions, if they can show a high
rate of success when their internally
funded new hires go into the retro-
spective review program, would
be able to outcompete the present
block grant holders whose new
hire success rate is at the low end
of the scale and capture the block
funding going forward. So the sys-
tem can accommodate changes in
institutional strength over time.
2. What about the geographic distri-
bution of funding and the concern
of Representatives and Senators
about institutions in their districts/
states? Again, the distribution is
not different from what exists now,
so it is unclear there would be
reason for complaint, but of course,
this issue isn’t always debated in a
completely dispassionate manner.
I am not such a purist that I don’t
see some value in insuring minimal
base funding for major (state) insti-
tutions even if their historical record
wouldn’t support making a large
block award (though I note that
many state universities are strong
research centers). This is not just
for political reasons. Often such
institutions are the only places
some students can afford to go to
college, and exposing these stu-
dents to active research would8 Cell 161, June 18, 2015 ª2015 Elsevier Incallow capture of some potentially
outstanding future scientists who
would otherwise lack mentors
and the experience of laboratory
research to propel them further in
this direction.
3. Is the recommendation for termina-
tion of funding at the end of any
given cycle due to ‘‘non-perfor-
mance’’ too harsh? Aside from the
exceptions listed for new investiga-
tors that would result in bridge
funding for 1–2 years (imminentma-
jor progress or investment in a
potentially important but risky proj-
ect), should the result of a poor
review for either the first or any sub-
sequent cycle be a drastic reduc-
tion in funding continued for a full
cycle rather than cessation of an
award, with the hope that such a
cut would lead the investigator to
focus intently on a limited question
and make sufficient progress to
pass muster at the next review?
I have doubts about this alterna-
tive—with 5–7 years of support
per round and 1–2 years of bridge
funding available, I think it is unlikely
that a highly competent investigator
will fail to produce enough during
6–9 years of research to warrant a
‘‘passing grade’’ without further
extensions, except in extenuating
circumstances. Further discussion
will be needed to develop a policy
dealing with accommodations
in grant term related to family and
health-related issues. It should
also be noted that the current R01
system possesses the same ‘‘defi-
ciencies,’’ as R01 renewal is also
a binary outcome. Although current
investigators with multiple grants
can afford to fail to renew some
funding sources without shutting
down their laboratories, in the plan
proposed here, PIs similarly funded
to perform a broad range of pro-
jects would also be ‘‘protected’’
against complete loss of funding
by being able to show progress in
subsets of these diverse projects.
A related issue is whether there
can and/or should be an opportu-
nity for additional funding during
the initial 5–7 year new faculty sup-
port period—for example, if an un-.expected result looks like it would
open a new area and there is a
desire to add work in that direction
to ongoing efforts. I think in the
main that the support I am propos-
ing should be adequate for the PI to
take advantage of such observa-
tions by terminating less productive
activities in the lab and redirecting
funds and personnel to this more
promising avenue. Of course,
some allowances may need to be
made at times in deference to grad-
uate student and postdoctoral
fellow career issues. There will
also be occasions when the nature
of the work is such that only addi-
tional funding will allow the new op-
portunity to be properly pursued,
so a limited number of awards in
support of such novel projects
could be part of the plan. I worry
that application for such funds
would quickly become routine, but
perhaps a mechanism to allow
such funding on rare occasions
could be found that avoids this
pitfall. One possibility is to give in-
stitutions the ability to hold back a
small fraction of their block grant
funds and disburse these in
response to requests from their
own investigators hired through
this mechanism. Such a scheme
wouldmake the institutions respon-
sible for ensuring that the money
waswell employed, as the outcome
of such supplemental awards
would be taken into account during
the institution block grant review
process that is based on the suc-
cess of the new career hires.
A last point on this topic is what to
do with rising stars who wish to
expand their laboratories earlier
than theusual 5–7 year point of entry
into the retrospective review sys-
tem. I think that there is every reason
to allow investigators to try their luck
with the review process earlier than
the maximally permitted period. It
is a risk of course in that those doing
the review may not agree that the
work is quite so stellar, so I suspect
only those with the strongest pro-
grams will opt for this possibility.
This makes it likely that only a small
number of such early renewals with
a request for expansionwill come in,
and I see no reason to deny such
(putatively) successful PIs a chance
to build more rapidly.
4. The description of this change in
funding is cast above as if NIH is
a monolithic organization, but of
course, it consists of nearly two-
dozen institutes that make grant
awards. Substantial thought (and
political will) will be necessary to
put this plan into operation in the
context of the separate budgets
for these institutes and their
different primary areas of research
support. This is not a simple matter
to parse, as the most obvious solu-
tion requires some adjustment of
budgets among institutes (a politi-
cally fraught issue), but if the basic
tenets of the proposal are accepted
as desirable goals, I believe this
problem can be resolved.
5. This proposal does not deal explic-
itly with the difficulties that exist in
creating more opportunities for
minority and underserved popu-
lations to enter and succeed in
the biomedical research arena.
Augmenting such representation
requires changes at all stages
of education before the faculty en-
try point of the funding system
described here. However, I do think
that this scheme provides those
who make it to the first tier in such
a career (a junior faculty appoint-
ment) a more egalitarian path
forward based on documented per-
formance with resources in hand,
a process that is typically more
objective than project review. This
can only have a salutary effect in
fostering a more diverse population
of investigators. Nonetheless, spe-
cial attention will need to be paid
to ensuring that biases, subcon-
scious or otherwise, do not skew
the choices of new faculty or the
retrospective renewal process.
6. Mechanisms will be needed to deal
with gaps in research careers or
entry into the system other than as
a starting faculty member. Interrup-
tion of a research career for short
periods, for health or family rea-
sons, shouldn’t exclude an individ-
ual from continuing to function asa PI. For those already successfully
competing in the proposed system,
it should be reasonably straightfor-
ward to craft mechanisms for post-
poning ongoing funding for short
periods (a few years at most) and
then restarting the flow of dollars
when the individual returns to the
laboratory. In other cases, individ-
uals might wish to enter a research
track later in their career, whether
an M.D. moving from clinical work
to research or someone who has
been in a lab but not functioning
as a PI. Two ways to accommodate
such transitions could be easily
imagined—allowing institutions to
use some of their block funds to
initiate research careers for these
individuals, with the same post
hoc review of the success of these
choices, or reservation of a modest
amount of funding for direct appli-
cation in the style of the current
R01 system. Keeping open the pos-
sibility of entry into a research
career other than through the first
hire funding scheme that is at the
core of this proposal would help
ensure that the system isn’t a
‘‘one size fits all’’ that excludes
those who either come late to the
‘‘calling’’ or who may be on the
border of award of a funded junior
faculty position and need to prove
their worth in the research arena
to qualify for retrospective review
funding going forward.
7. Finally, although this proposal
deals primarily with R01 funding,
there will also need to be attention
paid to other mechanisms used for
research support. Large, collabora-
tive efforts are necessary to attack
certain problems. However, stron-
ger requirements for data qualifica-
tion, deposition, and sharing are
essential for larger projects sup-
ported by such mechanisms as
U01 or U19 awards, so that the sub-
stantial amount of money spent
on such efforts benefits the entire
research community and so that
the growing cadre of bioinfor-
maticians can re-use the data for
potentially novel discoveries at the
earliest possible time. I support
such large efforts, but not in theirCell 16current form—my experience is
that too often, vast sums are
consumed in disproportion to the
advances made, and in many
(most?) cases, the PIs feel that
they should have exclusive owner-
ship of the resources and data for
an unreasonably long time. There
should be stricter rules controlling
when data are made available pub-
licly and greater accountability to
insure investment translates into
outcome, especially when the ac-
tivities do not involve creation of
new technologies where success
cannot be assured, but rather
involve application of known
methods on a large scale to an
important problem (see the new
NIH rules on data access for
genomic information for efforts to
move forward in this direction [Na-
tional Institutes of Health, 2014]).
The issue of credit allocation and
career advancement for individuals
engaged in large, collaborative pro-
jects is also a crucial one but
beyond the scope of this piece,
though it may be instructive for
readers to examine the revisions
made in the past few years to the
NIH Intramural Research Program
tenure policy to specifically recog-
nize the importance of team sci-
ence in the biomedical research
arena (National Institutes of Health,
2015b).
I believe that, if changes along the lines I
propose could be accomplished, the
funds already available to the NIH would
be put to much better use. The review
process would become much less
onerous, with salutary effects on the re-
viewers (and on who is willing to serve in
such a position) and perhaps diminished
administrative costs and more funds
available for science itself. Indeed, review
panels could be much more multi-disci-
plinary than at present because of the
retrospective nature of the review that
considers mainly published work and is
not concerned with the discipline-specific
nitty-gritty of how one would conduct
a future study. Under such conditions,
one does not necessarily need to be
an expert in the field to contribute to
evaluation of the portfolio of the person1, June 18, 2015 ª2015 Elsevier Inc. 1489
under review—this was the case with the
HHMI when I was on the review board,
where having a mix of expertise on
the panel worked extremely well. This
broadening of the review boards would
decrease the perceived unevenness in
the rigor with which grants that go to
different study sections are reviewed, as
well as reduce the effects of parochial
thinking on the overall award pool and
research portfolio.
Many readers might suggest at this
point that I have missed a key issue—
the number of dollars devoted to
biomedical research. Wouldn’t many of
the problems I seek to rectify by this pro-
posal be obviated if there were simply
more money available? Others have
already noted that as desirable as an in-
crease in the NIH budget would be,
especially a correction of the 25%–30%
erosion in constant dollars that has
occurred over the past decade, it is
extremely unlikely that the problems af-
flicting the research enterprise can be
solved in this manner (Alberts et al.,
2014). The reason is simple math—de-
pending on what one considers the likely
size of laboratories (reliable data are
sparse and estimates range from as few
as 3–4 to 10+, as seems to be the case
from acknowledgment slides after talks
at major meetings of even junior faculty
speakers), then with 5 years on average
in postdoctoral training, each PI is repli-
cating herself or himself an average of
every 6 months to a year. Even if this
number is inflated by 2-fold due to sec-
ond postdoc periods, drop-outs from
the system, and non-trainee staff, and
assuming that only 25% of fellows
become PIs as has been reported
(Rockey, 2012), then the effective popu-
lation doubling rate is every 4–8 years. I
doubt any of us think that, however
much of the GDP we feel should be
devoted to biomedical research, the
compound budget increases approach-
ing the 12%–25% per year above infla-
tion needed to sustain such growth are
conceivable. The person-centric, block-
grant system I propose would impose
‘‘natural’’ population control through lim-
itations in the number of new laboratories
formed and their size expansion over
time. Together with other changes to
the sociology of scientific training and
to the structure of laboratory groups—1490 Cell 161, June 18, 2015 ª2015 Elseviermore research associates/staff scien-
tists, fewer trainees as mere hands in
the lab—a better balance between
potentially sustainable budget growth
and expansion of research can be at-
tained, while maintaining the creativity
that comes in large part from the influx
of new trainees and young investigators.
At the same time, this rebalancing of the
laboratory staff structure will improve
research efficiency. These changes
would also likely foster more collabora-
tion, given the constraints of overall
group size and the increasing apprecia-
tion that multidisciplinary efforts are often
needed to make major advances. I am
fairly sure we will not see the power law
budget increase needed to keep up
with the current explosive production
of new scientists arising from ongoing
practices, but I am perhaps unduly opti-
mistic that, after a correction of the infla-
tionary losses of the past several years,
we may be able to attain an ‘‘inflation
plus’’ growth rate that would support a
robust research enterprise of the type I
think we all envision and to which
this change in funding strategy could
contribute.
A final point of tension is over the frac-
tion of the budget devoted to basic versus
translational or clinical research, with a
fear among more basic investigators that
the balance is shifting too far toward the
latter (Wadman, 2012). There is little
doubt that successful translational work
that improves human health (the end
goal of the overall NIH mission) depends
on new discoveries made in basic science
laboratories, and strangling the latter will
only diminish effective clinical advances.
But it is also fair for the society that
supports research to expect a return
on its investment. Beyond the funding
scheme changes that constitute the
heart of this essay, I end by noting that
there are ways to provide stable support
to basic investigators while also recruiting
their knowledge and talents more directly
in support of the rapid movement of dis-
coveries into the translational realm;
indeed, some of the mechanisms for
doing this can make basic scientists
more aware of new areas ripe for study
and also generate collaborative enter-
prises that together make for exciting
and rewarding scientific interactions. If
we are creative and open in our thinkingInc.about re-structuring not only the major
support scheme for biomedical research
from a project to a person-centric model
as I propose, but also in how we organize
our research efforts, it is not too difficult
to imagine a future in which much of
the angst about support and career
stability can be turned into a new era
of sustainable and rewarding research
activities, one that satisfies the ‘‘seeker’’
in each scientist while providing society
with the new knowledge and application
of this information that it deserves for its
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